Edema formation in congestive heart failure and the underlying mechanisms



aafp hypertension :: Article Creator

AAFP Does Not Endorse New Hypertension Guideline

The American Academy of Family Physicians (AAFP) has not endorsed the 2017 hypertension guideline released by the American Heart Association (AHA) and American College of Cardiology (ACC). The AAFP will continue to endorse the 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults from the Eighth Joint National Committee (JNC8), according to an AAFP press release.

The AAFP, which was not involved in generating the new AHA/ACC hypertension guideline, used the same review process for both the AHA/ACC and JNC8 blood pressure guidelines and found that there was more robust scientific evidence to support the 2014 guidelines, a major factor in the AAFP's decision.

David O'Gurek, MD, chair of the Commission on Health of the Public and Science for AAFP, noted that the JNC8 guideline "provided strong recommendations to family physicians and patients on appropriate treatment of hypertension."

While the 2017 AHA/ACC guideline used a system to grade the quality of evidence, background resources were not fully assessed and certain trials were heavily weighted while others were not, Dr O'Gurek added.

The two major contributing factors to the decision were the absence of a formatted review process and the lack of quality review for each study by the AHA/ACC. According to the AAFP review process, some parts of the new guidelines did not meet the organization's criteria.

Jennifer Frost, MD, the medical director for the AAFP Health of the Public and Science Division, stated that a positive point of the new hypertension guideline was that it stressed the importance of proper technique and validated device usage for at-home blood pressure monitoring systems.

[hmicms_related_articles]

Dr Frost added that another positive from the new guideline is the emphasis on healthy lifestyle choices to reduce the risk of hypertension, which "is important for all individuals, whether or not they have a diagnosis of hypertension." 

  • AAFP decides to not endorse AHA/ACC hypertension guideline. Crawford C. [Press-Release]. American Academy of Family Physicians. Dec 12 2017. Accessible at: https://www.Aafp.Org/news/health-of-the-public/20171212notendorseaha-accgdlne.Html

    • AAFP Says It Cannot Endorse New Hypertension Guideline

    The American Academy of Family Physicians (AAFP) announced last week that it has decided to not endorse the new hypertension guideline from the American College of Cardiology (ACC), the American Heart Association (AHA), and nine other partnering bodies.

    Instead, the organization continues to endorse guidance released at the end of 2013 by a group originally empaneled as the Eight Joint National Committee (JNC8), which declined to join the ACC/AHA process for developing guidelines after the National Heart, Lung, and Blood Institute handed over responsibility for doing so.

    "Based on the methodology, applicability, and consistency within the JNC8 guideline, the AAFP felt strongly that the JNC8 upheld the scientific rigor that provided strong recommendations to family physicians and patients on appropriate treatment of hypertension,David O'Gurek, MD, chair of the AAFP's Commission on Health of the Public and Science, said in AAFP News, a publication produced by the association.

    The ACC/AHA hypertension guideline, released during the AHA 2017 Scientific Sessions last month to largely positive reviews, made two major changes: lowering the recommended treatment goal to less than 130/80 mm Hg across patient groups and reclassifying hypertension so that treatment with lifestyle changes and/or medication is recommended beginning when blood pressure is 130/80 mm Hg or higher. When the guidance was first released, experts who spoke with TCTMD emphasized that "buy-in" from primary care physicians would be essential for the new document to have a meaningful impact.

    Now, having reviewed the guideline, the AAFP says it falls short of their standards for endorsement for the following reasons:

  • Most of the recommendations were not based on a systematic review of the evidence. Although a systematic review was performed, it addressed only four key questions and did not assess harms associated with aiming for lower blood pressure goals.
  • Assessments of the quality of individual studies or systematic reviews were not provided.
  • The SPRINT trial was given too much weight at the expense of other studies.
  • The guideline recommends using the ACC/AHA atherosclerotic cardiovascular disease risk calculator to determine whether medication is needed in certain patients, despite the fact that evidence showing the tool improves outcomes is lacking.
  • There are concerns about potential conflicts of interest, with the head of the SPRINT trial serving as chair of the writing committee for the new guideline and other guideline writers having intellectual conflicts of interest that were not addressed.

    • In January 2017, the AAFP and American College of Physicians (ACP) released their own guideline for patients 60 and older. Similar to what is recommended by JNC8, they advise starting treatment in patients with a systolic pressure of 150 mm Hg or higher and aiming for goal below that threshold. That is much less aggressive than the recommendation in the new ACC/AHA guideline.

    Though systematic reviews suggest that going even lower with blood pressure reduces cardiovascular events, there are no benefits seen in terms of all-cause mortality, CV mortality, MI, or renal events.

    "Therefore, the AAFP and ACP recommended considering treatment to lower targets for some patients in the context of shared decision-making," according to the AAFP News publication.

    The nine organizations that joined ACC/AHA in crafting the new guideline were the American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Geriatrics Society, American Pharmacists Association, American Society of Hypertension, American Society for Preventive Cardiology, National Medical Association, and Preventive Cardiovascular Nurses Association.


    ACP/AAFP Recommend BP Target Goals In Older Hypertensive Patients

    This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.





    Comments

    Post a Comment

    Popular posts from this blog

    Roseola vs. measles rash: What is the difference? - Medical News Today

    Image
    Roseola and measles are two different diseases that present with a high fever and a rash. They are both most commonly seen in childhood, although measles can affect people of any age, and roseola in adults is very rare. While both diseases share similarities, there are distinguishing factors, such as how the symptoms present and the disease progression. Read on to find out the difference between roseola and measles rashes. Roseola, also known as roseola infantum, sixth disease, or exanthema subitum, is a viral infection that typically affects children. The human herpesvirus 6 (HHV-6) or human herpesvirus 7 (HHV-7) causes roseola. The disease is spread through tiny respiratory droplets that people either breathe in or pick up from surfaces they touch. This disease usually presents in children between the ages of 6–12 months . Children who have this disease experience a high fever, followed by a pink or red rash. Roseola is a self-limiting viral illness, meaning it will typically go awa...
    Read more

    Athlete's foot: Symptoms, types, causes, treatment, prevention - Insider

    Image
    Athlete's foot is a fungal infection that causes itchy, flaky skin between toes and on foot soles. You may also experience foul-smelling feet and changes in skin color depending on what type you have. You should start to feel relief about two weeks after starting treatment. Visit Insider's Health Reference library for more stories. Athlete's foot, also known as tinea pedis, is a type of fungal infection called ringworm that affects the feet. It occurs most commonly between the toes or on the soles of the feet. Athlete's foot is quite common and is estimated to affect 3%-15% of people Contrary to the name, you don't have to be an athlete to contract it. The name came about because it is commonly caught and spread in places athletes frequent like gyms and locker rooms.  But the fungus thriv...
    Read more

    Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association

    Image
    causes of precapillary pulmonary hypertension :: Article Creator Long-term Oxygen Therapy Improves Exercise Capacity In PH Long-term oxygen improves exercise capacity in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. Twelve weeks of supplemental oxygen led to a significant and clinically relevant improvements in exercise capacity, as assessed with the six-minute walking distance test (6MWD), by 42 meters (about 138 feet) over the distances walked at start of the study, "Long-term oxygen therapy in precapillary pulmonary hypertension — SOPHA study," which was published in Scientific Reports. PH is marked by high blood pressure in the pulmonary arteries, the blood vessels that transport blood from the heart to the lungs. Precapillary PH includes PAH, where blood pressure increases due to the narrowing of pulmonary arteries, along with CTEPH, a rare form of p...
    Read more